Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513779-42-02

Enrollment

100

Registered

2025-02-12

Start date

2025-03-27

Completion date

Unknown

Last updated

2025-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

1) Disease control (objective complete or partial response or stable disease) at 16 weeks after treatment initiation according to established response criteria, 2) Treatment-related grade ≥3 and serious adverse events for all cohorts., 3. Treatment-related grade 1-5 adverse events for cohorts with new treatment combinations

Detailed description

1) Progression-free survival, 2) Overall survival, Duration of time on drug

Interventions

DRUGMekinist 2 mg film-coated tablets

DRUGMekinist 0.5 mg film-coated tablets

DRUGTafinlar 75 mg hard capsules

DRUGIMATINIB

DRUGTafinlar 50 mg hard capsules

DRUGTevimbra 100 mg concentrate for solution for infusion

DRUGFinlee 10 mg dispersible tablets

DRUGSpexotras 0.05 mg/ml powder for oral solution

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1) Disease control (objective complete or partial response or stable disease) at 16 weeks after treatment initiation according to established response criteria, 2) Treatment-related grade ≥3 and serious adverse events for all cohorts., 3. Treatment-related grade 1-5 adverse events for cohorts with new treatment combinations	—

Secondary

Measure	Time frame
1) Progression-free survival, 2) Overall survival, Duration of time on drug	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026